Streptococcus pneumoniae Serotypes Identified in Mexican Children with Invasive Disease Before and After the Introduction of PCV7 (1993–2012)

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world

“…Despite the availability of PCV, among the 21 studies assessing IPD among children, serotypes included in PCV accounted for >60% of the total serotypes in 11 reports. 6,11,12,14,[16][17][18][19][20][21][22] Serotype 19A was among the most commonly identified in all of the geographic regions included in this review. In addition, serotypes 1 and 14 were prominent in Europe and Latin America and serotypes 6B, 14 and 19F were important in Africa-East Mediterranean, demonstrating geographic variations in the prevalence of PCV serotypes among pediatric IPD cases.…”

Sistema Regional de Vacunas (SIREVA), vigilancia por laboratorio y desarrollo de vacunas para Streptococcus pneumoniae: análisis bibliométrico, 1993-2019

“…La visualización superpuesta o temporal reveló con claridad la evolución de los temas de investigación en el terreno de S. pneumoniae en la Región, probablemente similar a lo que ocurre a nivel global ( figuras 4a y b ). Los términos relacionados con tipos capsulares, antibióticos, sensibilidad antimicrobiana, concentración inhibitoria mínima (CIM), resistencia de nivel alto e intermedio, se asocian con las publicaciones de los años 90 ( 6 - 8 , 10 - 12 ), seguidas por términos relacionados con clones, electroforesis por campo pulsado (PFGE, por su sigla en inglés), relaciones genéticas ( 9 , 14 ) y continúan con términos usados en publicaciones más recientes como tipificación multilocus de secuencias (MLST, por su sigla en inglés), reacción en cadena de la polimerasa (PCR, por su sigla en inglés), portadores, vacunas, vacunas conjugadas (PCV) y los términos nuevos como son PCV7, PCV10 y PCV13, evaluación, efectividad, y reducción ( 13 , 28 , 34 , 35 ).…”

The effects of pneumococcal conjugate vaccine (PCV7 and PCV13) on Turkish children with invasive pneumococcal disease: a single center experience

“…17 In Mexican children, there was a significant decrease in all PCV7 serotypes as from 59.7% to 21% and a gradual increase of the serotype 19A was detected from 7% to 39%. 18 But, after the implementation of PCV13 there was a 75% reduction in overall IPD and no cases of serotype 19A. 19 In a systematic review about the impact and effectiveness of PCV10 and PCV13 on hospitalization and mortality in children aged less than 5 years in Latin American countries (Brazil, Chile, Uruguay, Argentina, Peru and Nicaragua), the hospitalization rates of X-ray confirmed pneumonia, meningitis and IPD were declined 8.8-37.8%, 13.3-87.7% and 56-83.3%, respectively.…”